Expression of Metastasis-associated Protein 3 in Human Brain Glioma Related to Tumor Prognosis

Overview

Journal Neurol Sci

Specialty Neurology

Date 2015 May 24

PMID 26002011

Citations 11

Authors

ShouQin Shan

Guangyan Hui

Fanggao Hou

Hua Shi

Guoqing Zhou

Han Yan

Lu Wang

Jinfeng Liu

Affiliations

Soon will be listed here.

Abstract

Glioma represents a disparate group of tumors characterized by high invasion ability, and therefore it is of clinical significance to identify molecular markers and therapeutic targets for better clinical management. Previously, metastasis-associated protein family (MTA) is considered to promote tumor cell invasion and metastasis of human malignancies. Recently, the newly identified MTA3 has been shown to play conflicting roles in human malignancies, while the expression pattern and potential clinical significance of MTA3 in human glioma have not been addressed yet. In the present study, we investigated the protein expression of MTA3 by immunohistochemistry assay and analyzed its association with glioma prognosis in 186 cases of patients. Results showed that MTA3 expression was decreased in glioma compared with that in normal brain (P < 0.05). In addition, tumors with high MTA3 expression were more likely to be of low WHO grade (P = 0.005) and reserve of body function (P = 0.014). Survival analysis showed that decreased MTA3 expression was independently associated with unfavorable overall survival of patients (P < 0.001). These results provide the first evidence that MTA3 expression was decreased in human glioma and negatively associated with prognosis of patients, suggesting that MTA3 may play a tumor suppressor role in glioma.

Citing Articles

MTA3 Represses Cancer Stemness by Targeting the SOX2OT/SOX2 Axis.

Du L, Wang L, Gan J, Yao Z, Lin W, Li J iScience. 2019; 22:353-368.

PMID: 31810000 PMC: 6909183. DOI: 10.1016/j.isci.2019.11.009.

MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma.

Yao Z, Du L, Xu M, Li K, Guo H, Ye G Front Oncol. 2019; 9:816.

PMID: 31552166 PMC: 6736560. DOI: 10.3389/fonc.2019.00816.

Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adults.

Bartlett A, Liang J, Sandoval-Sierra J, Fowke J, Simonsick E, Johnson K Biomark Res. 2019; 7:10.

PMID: 31149338 PMC: 6537435. DOI: 10.1186/s40364-019-0161-3.

Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.

Pfeifer A, Rusinek D, Zebracka-Gala J, Czarniecka A, Chmielik E, Zembala-Nozynska E Genes Chromosomes Cancer. 2019; 58(8):558-566.

PMID: 30664823 PMC: 6594006. DOI: 10.1002/gcc.22737.

Risk assessment model constructed by differentially expressed lncRNAs for the prognosis of glioma.

Hu C, Zhou Y, Liu C, Kang Y Oncol Rep. 2018; 40(5):2467-2476.

PMID: 30106138 PMC: 6151882. DOI: 10.3892/or.2018.6639.

References

Noll K, Sullaway C, Ziu M, Weinberg J, Wefel J . Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol. 2014; 17(4):580-7. PMC: 4483071. DOI: 10.1093/neuonc/nou233. View

Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M . NDRG1 prognosticates the natural course of disease in WHO grade II glioma. J Neurooncol. 2014; 117(1):25-32. DOI: 10.1007/s11060-013-1357-2. View

Covington K, Fuqua S . Role of MTA2 in human cancer. Cancer Metastasis Rev. 2014; 33(4):921-8. PMC: 4425804. DOI: 10.1007/s10555-014-9518-0. View

Hofer M, Menke A, Genze F, Gierschik P, Giehl K . Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br J Cancer. 2004; 90(2):455-62. PMC: 2409548. DOI: 10.1038/sj.bjc.6601535. View

Bruning A, Juckstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I . The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol. 2010; 25(11):1447-56. DOI: 10.14670/HH-25.1447. View

Liu S, Han Y, Zhang Y, Xie C, Wang E, Miao Y . Expression of metastasis-associated protein 2 (MTA2) might predict proliferation in non-small cell lung cancer. Target Oncol. 2012; 7(2):135-43. DOI: 10.1007/s11523-012-0215-z. View

Dong H, Guo H, Xie L, Wang G, Zhong X, Khoury T . The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. PLoS One. 2013; 8(5):e62986. PMC: 3643958. DOI: 10.1371/journal.pone.0062986. View

Fearon E . Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer. Cancer Cell. 2003; 3(4):307-10. DOI: 10.1016/s1535-6108(03)00087-4. View

Fujita N, Jaye D, Kajita M, Geigerman C, Moreno C, Wade P . MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003; 113(2):207-19. DOI: 10.1016/s0092-8674(03)00234-4. View

10.

Liu J, Wang H, Huang C, Qian H . Subcellular localization of MTA proteins in normal and cancer cells. Cancer Metastasis Rev. 2014; 33(4):843-56. DOI: 10.1007/s10555-014-9511-7. View

11.

Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M . BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015; 33(9):1015-22. PMC: 4356711. DOI: 10.1200/JCO.2014.58.3922. View

12.

Di Stefano A, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P . Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res. 2015; 21(14):3307-17. PMC: 4506218. DOI: 10.1158/1078-0432.CCR-14-2199. View

13.

Yoo Y, Na T, Seo H, Seong J, Park C, Shin Y . Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene. 2008; 27(24):3405-13. DOI: 10.1038/sj.onc.1211000. View

14.

Mangla R, Ginat D, Kamalian S, Milano M, Korones D, Walter K . Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol. 2013; 116(2):325-31. DOI: 10.1007/s11060-013-1298-9. View

15.

Le Rhun E, Taillibert S, Chamberlain M . The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int. 2015; 6(Suppl 1):S9-S44. PMC: 4338495. DOI: 10.4103/2152-7806.151331. View

16.

Mur P, de Lope A, Diaz-Crespo F, Hernandez-Iglesias T, Ribalta T, Fiano C . Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. J Neurooncol. 2015; 122(3):441-50. DOI: 10.1007/s11060-015-1738-9. View

17.

Jang K, Paik S, Chung H, Oh Y, Kong G . MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006; 97(5):374-9. PMC: 11159072. DOI: 10.1111/j.1349-7006.2006.00186.x. View

18.

Kumar R . Another tie that binds the MTA family to breast cancer. Cell. 2003; 113(2):142-3. DOI: 10.1016/s0092-8674(03)00274-5. View

19.

Zhou C, Ji J, Cai Q, Shi M, Chen X, Yu Y . MTA2 promotes gastric cancer cells invasion and is transcriptionally regulated by Sp1. Mol Cancer. 2013; 12(1):102. PMC: 3851872. DOI: 10.1186/1476-4598-12-102. View

20.

Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E . IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol. 2013; 15(4):469-79. PMC: 3607260. DOI: 10.1093/neuonc/nos317. View